JP6192294B2 - グラム陽性菌特異的結合化合物 - Google Patents

グラム陽性菌特異的結合化合物 Download PDF

Info

Publication number
JP6192294B2
JP6192294B2 JP2012520555A JP2012520555A JP6192294B2 JP 6192294 B2 JP6192294 B2 JP 6192294B2 JP 2012520555 A JP2012520555 A JP 2012520555A JP 2012520555 A JP2012520555 A JP 2012520555A JP 6192294 B2 JP6192294 B2 JP 6192294B2
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
light chain
framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012520555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533293A (ja
Inventor
ティム ボーモント，
ティム ボーモント，
マルク イエロエン クワーケンボス，
マルク イエロエン クワーケンボス，
エリック ジェイ． ブラウン，
エリック ジェイ． ブラウン，
ジョン ヒロシ モリサキ，
ジョン ヒロシ モリサキ，
ウーター エル． ダブリュ． ヘイゼンボス，
ウーター エル． ダブリュ． ヘイゼンボス，
サンジーヴ マリアザサン，
サンジーヴ マリアザサン，
キンバリー カジハラ，
キンバリー カジハラ，
シャ，ユィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2012533293A publication Critical patent/JP2012533293A/ja
Application granted granted Critical
Publication of JP6192294B2 publication Critical patent/JP6192294B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2012520555A 2009-07-15 2010-07-15 グラム陽性菌特異的結合化合物 Expired - Fee Related JP6192294B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
US61/225,878 2009-07-15
EP09165558.9 2009-07-15
EP09165558 2009-07-15
PCT/NL2010/050456 WO2011008092A2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001939A Division JP2016135771A (ja) 2009-07-15 2016-01-07 グラム陽性菌特異的結合化合物

Publications (2)

Publication Number Publication Date
JP2012533293A JP2012533293A (ja) 2012-12-27
JP6192294B2 true JP6192294B2 (ja) 2017-09-06

Family

ID=41467048

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012520555A Expired - Fee Related JP6192294B2 (ja) 2009-07-15 2010-07-15 グラム陽性菌特異的結合化合物
JP2016001939A Pending JP2016135771A (ja) 2009-07-15 2016-01-07 グラム陽性菌特異的結合化合物
JP2018072444A Pending JP2018134089A (ja) 2009-07-15 2018-04-04 グラム陽性菌特異的結合化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016001939A Pending JP2016135771A (ja) 2009-07-15 2016-01-07 グラム陽性菌特異的結合化合物
JP2018072444A Pending JP2018134089A (ja) 2009-07-15 2018-04-04 グラム陽性菌特異的結合化合物

Country Status (24)

Country Link
US (9) US20110020323A1 (enExample)
EP (1) EP2454284B1 (enExample)
JP (3) JP6192294B2 (enExample)
KR (1) KR101832201B1 (enExample)
CN (2) CN102666583B (enExample)
AR (1) AR077756A1 (enExample)
AU (2) AU2010271582B2 (enExample)
BR (1) BR112012000953A8 (enExample)
CA (1) CA2768204A1 (enExample)
DK (1) DK2454284T3 (enExample)
EA (1) EA031447B1 (enExample)
ES (1) ES2673323T3 (enExample)
HK (1) HK1222418A1 (enExample)
HU (1) HUE038277T2 (enExample)
IL (3) IL217497A (enExample)
MX (1) MX350234B (enExample)
NZ (2) NZ598063A (enExample)
PL (1) PL2454284T3 (enExample)
SG (2) SG177653A1 (enExample)
SI (1) SI2454284T1 (enExample)
TR (1) TR201809128T4 (enExample)
TW (2) TW201610153A (enExample)
WO (1) WO2011008092A2 (enExample)
ZA (2) ZA201200363B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021001906B1 (pt) 2005-12-09 2022-03-29 Kling Biotherapeutics B.V. Método para aumentar a estabilidade de uma célula produtora de anticorpo, método para produzir uma célula produtora de anticorpo que é estável durante pelo menos uma semana, método para produzir linhagem de células b, e método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
ES2666584T3 (es) 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
PT2646466T (pt) 2010-12-02 2017-06-07 Aimm Therapeutics Bv Meios e métodos para produzir anticorpos de alta afinidade
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2890427C (en) 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
US9809645B2 (en) 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
US9884126B2 (en) * 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
MX369022B (es) * 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
ES2729057T3 (es) 2013-12-17 2019-10-30 Aimm Therapeutics Bv Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
WO2016090038A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192175A1 (en) 1994-06-07 1995-12-21 Ambrose Cheung Surface protein of staphylococcus aureus
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
AU4714196A (en) * 1995-01-30 1996-08-21 Peter Truog Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6635473B1 (en) 1998-08-31 2003-10-21 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
WO2000012131A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
BR0207068A (pt) 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004025416A2 (en) 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1631581A4 (en) * 2003-05-29 2006-10-18 Inhibitex Inc SDR PROTEINS FROM STAPHYLOCOCCUS CAPITIS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF INFECTIONS
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US8475798B2 (en) 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
AU2007221321B2 (en) 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
AU2008232903B9 (en) * 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
HUE031614T2 (en) 2008-01-31 2017-07-28 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Treatment of microbial infections
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections

Also Published As

Publication number Publication date
SG177653A1 (en) 2012-02-28
KR101832201B1 (ko) 2018-02-28
US20110020323A1 (en) 2011-01-27
KR20120065326A (ko) 2012-06-20
EP2454284A2 (en) 2012-05-23
IL238074A (en) 2016-06-30
JP2012533293A (ja) 2012-12-27
SG10201704269RA (en) 2017-06-29
WO2011008092A3 (en) 2011-05-26
PL2454284T3 (pl) 2018-09-28
ZA201400644B (en) 2015-10-28
JP2016135771A (ja) 2016-07-28
TW201107470A (en) 2011-03-01
MX350234B (es) 2017-08-30
US9399673B2 (en) 2016-07-26
CN105440133A (zh) 2016-03-30
US9266943B2 (en) 2016-02-23
HK1222418A1 (zh) 2017-06-30
US20130253175A1 (en) 2013-09-26
ZA201200363B (en) 2014-06-25
AR077756A1 (es) 2011-09-21
EA201390967A1 (ru) 2014-01-30
ES2673323T3 (es) 2018-06-21
IL242207A0 (en) 2015-11-30
CA2768204A1 (en) 2011-01-20
AU2010271582A2 (en) 2013-05-16
US20130261293A1 (en) 2013-10-03
AU2016250398A1 (en) 2016-11-17
US9927428B2 (en) 2018-03-27
EP2454284B1 (en) 2018-04-11
JP2018134089A (ja) 2018-08-30
NZ616921A (en) 2015-06-26
BR112012000953A2 (pt) 2016-11-22
US20170067880A1 (en) 2017-03-09
US9688745B2 (en) 2017-06-27
AU2010271582B2 (en) 2016-07-28
US20160222096A1 (en) 2016-08-04
CN102666583B (zh) 2015-11-25
NZ598063A (en) 2014-07-25
US8617556B2 (en) 2013-12-31
TWI502068B (zh) 2015-10-01
EA031447B1 (ru) 2019-01-31
WO2011008092A2 (en) 2011-01-20
US20150376266A1 (en) 2015-12-31
TW201610153A (zh) 2016-03-16
IL217497A (en) 2015-11-30
US9458228B2 (en) 2016-10-04
TR201809128T4 (tr) 2018-07-23
US20140235828A1 (en) 2014-08-21
US20180292391A1 (en) 2018-10-11
US20160168232A9 (en) 2016-06-16
US20120157665A1 (en) 2012-06-21
DK2454284T3 (en) 2018-07-02
HUE038277T2 (hu) 2018-10-29
WO2011008092A4 (en) 2011-07-07
SI2454284T1 (en) 2018-07-31
AU2016250398B2 (en) 2018-09-27
BR112012000953A8 (pt) 2017-12-26
AU2010271582A1 (en) 2012-03-01
IL217497A0 (en) 2012-02-29
US9090677B2 (en) 2015-07-28
CN102666583A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
JP6192294B2 (ja) グラム陽性菌特異的結合化合物
JP7041628B2 (ja) リポ多糖に特異的に結合する抗体分子－薬物コンジュゲートおよびその使用
CN107873034A (zh) 抗金黄色葡萄球菌抗体组合制剂
CA2810030A1 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
HK1171238B (en) Gram-positive bacteria specific binding compounds
HK1171238A (en) Gram-positive bacteria specific binding compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170808

R150 Certificate of patent or registration of utility model

Ref document number: 6192294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees